Navigation Links
Vein Removal Method Linked to Bypass Results
Date:7/15/2009

More long-term problems seen with minimally invasive technique

WEDNESDAY, July 15 (HealthDay News) -- A study originally designed for a completely different purpose has unearthed a disturbing finding about coronary artery bypass surgery: The way that the vein used for the bypass is removed from the body appears to affect the long-term outcome of the surgery.

People whose veins are removed by the minimally invasive technique called endoscopic harvesting had higher rates of bypass failure, heart attacks and death, according to a report in the July 16 issue of the New England Journal of Medicine.

The finding was entirely unexpected, said study senior author Dr. John H. Alexander, a cardiologist at Duke Clinical Research Institute. The study of 3,000 people who had bypass surgery was designed to determine whether treating the removed veins with a drug would improve results. (It didn't.) Only longer-term analysis of the study data revealed the difference in outcome between veins obtained by endoscopic harvesting and those obtained through conventional surgery.

"The mortality difference did not become apparent for at least nine or 10 months," Alexander said. "No one would have thought you needed a year or more to detect a difference in outcome."

Endoscopic harvesting, which uses a one- or two-inch incision to remove a saphenous vein from a leg, is used in 70 percent of the 450,000 coronary bypass operations done annually in the United States. Conventional surgery, which requires a much longer incision, is used in the other 30 percent of cases. Endoscopic harvesting is popular among surgeons and people having bypasses because it virtually eliminates the risk of infection, excess bleeding and other complications associated with conventional removal.

The journal report does not discuss those advantages. Instead, it focuses on the greater rate of graft failure (46.7 percent versus 38 percent at 18
'/>"/>

Copyright©2009 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. Headhunters Lice Removal Service Has Lice in Atlanta on the Run
2. CRH Medical introduces non surgical hemorroid removal to Gastroenterology Fellowship program
3. Lumenis High Speed LightSheer(R) Duet(TM) Featured on ABCs Good Morning America Health as the New Gold Standard for Laser Hair Removal
4. Palomar Successful in U.S. Patent Office Re-Examination of Hair Removal Patent
5. Palomar Receives FDA Over-The-Counter Clearance for a Home Use Wrinkle Removal Laser Device
6. Pain-Free, Hair-Free System Set to Transform Hair Removal
7. QLT Announces Court Response to Motion to Dismiss and Removal of Case to Federal Court
8. Palomar Wins Two European Hair Removal Patent Opposition Hearings
9. Lice Removal Salon Offers San Diego an Upscale Solution to an Undesirable Problem
10. TRIA Laser Hair Removal System Debuts on The Doctors
11. Palomar Medical to Market Quantels SINON Tattoo Removal Laser in the United States and Canada
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Vein Removal Method Linked to Bypass Results
Vein Removal Method Linked to Bypass Results
Breaking Medicine Technology:ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 2ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 3ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 4ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 5ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 6ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 7FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 2FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 3Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 2Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 3Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 4Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 5New iPhone Application for Anesthesiologists 51079 1New iPhone Application for Anesthesiologists 51079 2BullMarket com Updates Outlook on Healthcare IT Stocks 51074 1BullMarket com Updates Outlook on Healthcare IT Stocks 51074 2Health Caregivers and Allies to Rally 5 p m Weds in Fremont 51070 1Health Caregivers and Allies to Rally 5 p m Weds in Fremont 51070 2